Definition & Pathophysiology

Unstable angina (UA) is a form of acute coronary syndrome (ACS) characterized by myocardial ischemia at rest or with minimal exertion, due to dynamic obstruction from thrombus formation on a ruptured or eroded atherosclerotic plaque—without elevation of cardiac biomarkers above the 99th percentile upper reference limit (i.e., non–ST-elevation ACS). It represents an intermediate clinical entity between stable angina and non–ST-elevation myocardial infarction (NSTEMI), distinguished primarily by clinical context rather than troponin levels.

The underlying pathophysiology involves:

• Plaque rupture/erosion → exposure of subendothelial collagen and tissue factor → platelet adhesion/activation + coagulation cascade initiation → occlusive or subtotal thrombus.
• Vasospasm (Prinzmetal’s variant) may contribute in some cases, especially in smokers or those with endothelial dysfunction.
• Impaired coronary flow reserve due to microvascular dysfunction (especially in women and diabetic patients) can exacerbate ischemia.

Clinical implication: UA is not a “stable” precursor—it is an acute, high-risk event with 2–5% in-hospital mortality and >10% risk of myocardial infarction or death within 30 days if untreated (ESC ECS 2023).

Risk Stratification: TIMI & GRACE Scores

Prompt risk stratification is essential. The TIMI Risk Score for UA/NSTEMI (0–7 points) estimates 6-month mortality risk:

Key variables: age ≥65, ≥3 CAD risk factors (HTN, DM, family history, smoking, dyslipidemia), known coronary stenosis >50%, aspirin use in past 7 days, elevated cardiac biomarkers, ST-segment deviation on ECG.

The GRACE Risk Score (more comprehensive, includes admission vital signs, lab values, and in-hospital complications) better predicts in-hospital mortality and guides timing of invasive strategy (ACC 2023 update).

Practice pearl: In patients with UA and GRACE score >140 or TIMI ≥3, an early invasive strategy (within 2–24 hours) isClass I indication (ESC 2023; ACC/AHA 2023 Focus Update).

Clinical Presentation: Red Flags

UA typically presents with:

• New-onset severe angina (CCS class III–IV), or
• Crescendo pattern: increase in frequency, duration, or intensity of pre-existing angina, precipitated by lower exertional thresholds.
• Rest angina lasting >10 minutes, occurring at rest (especially nocturnal).
• Inadequate relief with nitroglycerin (>3 doses over 15 min).

Atypical presentations are common—particularly in elderly, women, and diabetics: epigastric pain, isolated dyspnea, fatigue, syncope, or anxiety/“impending doom.” Silent ischemia may occur in autonomic neuropathy.

Key distinction from stable angina: Temporal unpredictability, lack of consistent provocation, and persistence at rest. A new LBBB or new ST depression ≥2 mm in ≥2 contiguous leads on ECG strongly supports UA.

Diagnostic Workup: Beyond the basics

1. Electrocardiogram (ECG)

• ST-segment depression (≥0.5 mm in ≥2 leads) is most common; transient ST elevation suggests vasospasm or proximal occlusion.
• T-wave inversions (especially deep, symmetric) may follow ST changes.
• Normal ECG does not rule out UA: up to 50% of UA patients present with initially normal or nonspecific ECGs.

2. Cardiac Biomarkers

• High-sensitivity cardiac troponin (hs-cTnI or hs-cTnT): critical for distinguishing NSTEMI from UA.
  • UA: Undetectable or minimal rise (<upper reference limit [URL]), but may show low-level elevation if ischemia is prolonged (>1 hour).
  • Use 0/1-h or 0/2-h hs-cTn algorithms (ESC 2021): e.g., if baseline hs-cTn <5 ng/L and Δ<3 ng/L at 1h, very low risk of MI.
• CK-MB: less sensitive/specific than troponin but may help in re-infarction assessment.

3. Echocardiography

• Transthoracic echo (TTE): assesses wall motion abnormalities (regional hypokinesis), LV function, and complications (e.g., MR, VSD). A new regional wall motion abnormality supports ischemic etiology.
• Stress echocardiography: useful when ECG/biomarkers are inconclusive; >50% stenosis typically induces wall motion abnormalities under stress.

4. Imaging for Anatomic Assessment

• Coronary CT angiography (CCTA): excellent NPV (>99%) for excluding obstructive CAD in low-intermediate risk patients with chest pain. Not first-line in classic UA due to thrombus masking and arrhythmia risk during scan.
• Cardiac MRI: detects myocardial edema, microvascular obstruction, and non-obstructive CAD with high specificity (CMR in Ischemia Score >3 has 80% PPV for obstructive CAD).

5. Invasive Coronary Angiography (ICA)

• Gold standard for diagnosing UA/NSTEMI and guiding revascularization.
• Indications: high-risk features (dynamic ECG changes, hemodynamic instability, recurrent ischemia, elevated biomarkers), or plan for PCI/CABG.
• Critical findings: dominant left system involvement, multi-vessel disease with proximal LAD stenosis,collateral-dependent lesions.

Management: From Prehospital to Long-Term Care

A. Immediate (Prehospital & ED) Management

• MONA-BH is outdated; modern approach emphasizes:
  • Morphine: Only if ischemic pain persists despite nitrates + beta-blockers (limited use due to mortality risk in observational studies [JACC 2021]).
  • Oxygen: Only if SpO₂ <90% or signs of heart failure/shock. Hyperoxia may increase coronary vascular resistance.
  • Aspirin: 300–325 mg chewed (Class I, LOE B-R).
  • Nitroglycerin: SL or IV for ongoing ischemia; avoid if RV involvement or recent PDE5 inhibitor use.
  • Antiplatelets:
    • Ticagrelor (loading 180 mg) preferred over clopidogrel in UA/NSTEMI (PLACITUDE trial subanalysis; reduced stent thrombosis). Avoid in severe asthma/Bronchospasm.
    • Clopidogrel if ticagrelor unavailable or contraindicated (e.g., significant bradycardia).
  • Anticoagulation:
    • Enoxaparin (1 mg/kg SC BID) or bivalirudin (if PCI planned, especially high bleeding risk). Fondaparinux (2.5 mg SC daily) is alternative; avoid in CrCl <30 mL/min.
  • Early ECG monitoring: single-lead may miss dynamic changes—12-lead serial ECGs every 15–30 min if symptoms recurrent.

B. In-Hospital Medical Therapy

• Dual Antiplatelet Therapy (DAPT): Aspirin + P2Y₁₂ inhibitor for ≥12 months (unless high bleeding risk → consider 6 months).
• Beta-blockers: Start within 24–48h if no contraindications (HF, bradycardia, hypotension). Reduce mortality and MI recurrence (BEAUTIFUL trial meta-analysis).
• High-intensity statin: Atorvastatin 80 mg or rosuvastatin 20–40 mg daily—lowers LDL-C <70 mg/dL (goal for ACS). Pleiotropic effects: plaque stabilization, anti-inflammatory (CANTOS trial: canakinumab reduced events but not standard care).
• ACE inhibitors/ARBs: Class I in LVEF ≤40%, hypertension, DM, CKD. Start early if tolerated.
• Antianginals:
  • Long-acting nitrates: limited evidence for mortality benefit; symptomatic relief only.
  • Beta-blockers first-line for angina control.
  • Calcium channel blockers (dihydropyridines: amlodipine) if beta-blocker contraindicated or vasospastic component suspected.
  • Ranolazine: adjunctive therapy for refractory angina (ERA trial).

C. Revascularization Strategy

• Early invasive strategy (angiography within 2–24 hours): Recommended for:
  • Recurrent/ischemic chest pain at rest or with minimal activity
  • Dynamic ST-T changes
  • Hemodynamic instability or arrhythmias
  • Elevated biomarkers + new wall motion abnormality
• Delayed invasive strategy (>24–72 h) may be considered in lower-risk patients (e.g., GRACE <109).
• PCI vs CABG:
  • PCI preferred for single- or dual-vessel disease without complex anatomy.
  • CABG favored for:
    • Left main >50% stenosis
    • Three-vessel disease with diabetes or reduced LV function (SYNTAX score ≥33)
    • Proximal LAD + other lesions (“left main equivalent”)

Evidence: ISCHEMIA trial (2020) showed no mortality benefit of invasive vs conservative strategy in stable ischemic heart disease—but UA is not stable. In UA/NSTEMI, early revascularization improves outcomes regardless of GRACE score >140 (EUROASPIRE V).

D. Secondary Prevention & Lifestyle Modification

• Cardiac rehab: Class I recommendation—reduces mortality by 25% (ACC 2023 update). Structured exercise, education, and psychological support.
• Risk factor control:
  • LDL-C <55 mg/dL for very high-risk ACS patients (2019 ESC guidelines)
  • BP <130/80 mmHg (ACC/AHA 2017)
  • HbA1c <7% in diabetics
• Smoking cessation: 40–50% reduction in recurrent events within 1 year.
• Diet: Mediterranean pattern—rich in omega-3, fiber, antioxidants; low in saturated fats and processed carbs (PREDIMED trial).
• Psychosocial support: Depression increases mortality 2-fold post-MI (MOOD-TIMI 36). Screen with PHQ-9.

Controversies & Emerging Data

1. Anti-inflammatory therapy: Colchicine 0.5 mg daily reduced MI/stroke by 31% in LoDoCo2 and COLCOT trials—now Class IIb recommendation per 2023 ESC ACS guidelines.
2. SGLT2 inhibitors: Empagliflozin (EMPA-REG OUTCOME) and dapagliflozin (DECLARE-TIMI 58) show CV mortality benefit in high-risk DM patients; under study in nondiabetic HF/ACS (DELIVER, EMPEROR-Reduced).
3. PCSK9 inhibitors: In FOURIER, evolocumab reduced MI by 20% in ACS patients with residual LDL-C >70 mg/dL—consider in select high-risk cases despite max statin + ezetimibe.

Key Takeaways for Clinical Practice

• UA = acute, high-risk ischemia—treat asACS until proven otherwise.
• ** hs-cTn + serial ECGs + TIMI/GRACE scoring** guide diagnosis and management intensity.
• Early DAPT + anticoagulation + beta-blocker + statin forms the medical backbone.
• Invasive strategy within 24h is standard for moderate-high-risk UA—do not delay for “stable” presentations.
• Long-term, focus on aggressive risk factor modification and cardiac rehab to reduce recurrent events.

Sources: 2023 ESC Guidelines for the Management of ACS; 2023 ACC/AHA/ACCP/HRS Guideline Update for the Evaluation and Management of Patients with Chest Pain; JACC Reviews 2024; NEJM (PLACITUDE, ISCHEMIA, COLCOT); Lancet ( FOURIER).